Apoferritin-mediated doxorubicin internalization through transferrin receptor 1

Simple item page
dc.contributor.authorKrausová, Kateřinacs
dc.contributor.authorDostálová, Simonacs
dc.contributor.authorHynek, Davidcs
dc.contributor.authorKřížková, Soňacs
dc.contributor.authorAdam, Vojtěchcs
dc.contributor.authorHeger, Zbyněkcs
dc.date.issued2017-12-31cs
dc.description.abstractThis work is aimed at the possibilities of targeted drug delivery into the tumour tissue. This approach can greatly reduce the otherwise serious side effects of conventional treatment - systemic toxicity. For this purpose, ubiquitous protein cage apoferritin was employed as a carrier of cytotoxic drugs. Its molecule size of 10-12 nm allows it to employ the effect of increased permeability and retention as well as to avoid renal clearance. The cellular uptake of this carrier is known to be mediated via the transferrin receptor 1 (TfR1), which is overexpressed on metabolically highly active cells, such as cancer cells. Therefore, apoferritin's ability to deliver drug molecules to site-of-action was tested using cell lines with high, medium and low expression of TfR1. The optimal conditions for studying the expression of TfR1 using western blotting were as follows: lysate of 50,000 cells applied in non-reducing non-denaturing buffer and the concentration of the primary antibody of 1.0 µg/mL. The properties of encapsulated doxorubicin were not affected by apoferritin, thus preserving its toxicity for cells with high level of TfR1expression (30% growth inhibition of these cells after 24 h of treatment). The suitable usage of apoferritin as a nanocarrier for chemotherapeutic delivery was confirmed in this work.en
dc.formattextcs
dc.format.extent894-899cs
dc.format.mimetypeapplication/pdfcs
dc.identifier.citationMendelNet 2017. 2017, p. 894-899.en
dc.identifier.isbn978-80-7509-529-9cs
dc.identifier.orcid0000-0002-7318-6470cs
dc.identifier.orcid0000-0002-0479-8369cs
dc.identifier.orcid0000-0002-8527-286Xcs
dc.identifier.orcid0000-0002-3915-7270cs
dc.identifier.other148745cs
dc.identifier.researcheridE-5702-2012cs
dc.identifier.researcheridE-9617-2012cs
dc.identifier.researcheridD-7686-2012cs
dc.identifier.researcheridD-1973-2013cs
dc.identifier.urihttp://hdl.handle.net/11012/84176
dc.language.isoencs
dc.publisherMendel University in Brnocs
dc.relation.ispartofMendelNet 2017cs
dc.relation.urihttps://mendelnet.cz/artkey/mnt-201701-0102_Apoferritin-mediated-doxorubicin-internalization-through-transferrin-receptor-1.php?back=/magno/mnt/2017/mn1.php?secid=4cs
dc.rights(C) Mendel University in Brnocs
dc.rights.accessopenAccesscs
dc.subjectApoferritinen
dc.subjectcanceren
dc.subjectdoxorubicinen
dc.subjectnanomedicineen
dc.titleApoferritin-mediated doxorubicin internalization through transferrin receptor 1en
dc.type.driverconferenceObjecten
dc.type.statusPeer-revieweden
dc.type.versionpublishedVersionen
sync.item.dbidVAV-148745en
sync.item.dbtypeVAVen
sync.item.insts2025.02.03 15:40:07en
sync.item.modts2025.01.17 15:19:11en
thesis.grantorVysoké učení technické v Brně. Fakulta elektrotechniky a komunikačních technologií. Ústav biomedicínského inženýrstvícs
thesis.grantorVysoké učení technické v Brně. Středoevropský technologický institut VUT. Chytré nanonástrojecs
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
MendelNet_mnt2017010102.pdf
Size:
276.2 KB
Format:
Adobe Portable Document Format
Description:
MendelNet_mnt2017010102.pdf
Download
Collections
Ústav biomedicínského inženýrství
Chytré nanonástroje